BriaCells Lead Candidate Combined With KEYTRUDAÂ Strong Evidence of Rapid Additive or Synergistic AntiTumor Activity

BriaCell’s Lead Candidate Combined With KEYTRUDA®: Strong Evidence of Rapid Additive or Synergistic Anti-Tumor Activity

08:53 EDT 3 Apr 2019 | Investing News Network

BriaCell Therapeutics Corp. (TSX:BCT, OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced early efficacy data of BriaCell’s novel immunotherapy, Bria-IMT™, in combination with pembrolizumab [KEYTRUDA®; manufactured by Merck & Co., Inc. (NYSE: MRK)] (the “Combination Study”) in advanced breast cancer patients.

BriaCells Lead Candidate Combined With KEYTRUDAÂ Strong Evidence of Rapid Additive or Synergistic AntiTumor Activity

BriaCell’s Lead Candidate Combined With KEYTRUDA®: Strong Evidence of Rapid Additive or Synergistic Anti-Tumor Activity

More From BioPortfolio on "BriaCell’s Lead Candidate Combined With KEYTRUDA®: Strong Evidence of Rapid Additive or Synergistic Anti-Tumor Activity"